Propelling Immunotherapy Combinations Into the Clinic
This review summarizes promising new targets and immunotherapy combination strategies currently under clinical development.
Neoadjuvant Chemotherapy for Resectable Non–Small-Cell Lung Cancer
Lung cancer is the most common cancer diagnosed in men and women in the United States, and is the leading cause of cancer death.Over 160,000 individuals died as a result of lung cancer in 2008.[1] This number amounted to more than the number of deaths from colon, breast, and prostate cancers combined. The majority of lung cancer cases are non–small-cell lung cancer (NSCLC), and the poor outcomes are attributed to the high rate of metastases associated with this disease.